stockrow
Saturday 7 November 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
- EPS
- −331.8%
- Free cash flow
- −7.91%
Quarter to June 2026, against a year earlier
15.35
0.11
+0.72%
Follow MLYS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 88 | 88 | 252 | +69.3% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | (3) | (19) | (30) | (72) | (178) | (155) | (350) | +114.2% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | (3) | (19) | (30) | (72) | (178) | (155) | (350) | +114.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.74) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) | (4.24) | +25.3% | ||||||
| Cash flow | — | — | — | — | (0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.10) | (1.64) | +31.7% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.11) | (1.64) | +31.7% | ||||||
| Book value | — | — | — | — | (0.78) | (4.60) | (10.12) | 6.66 | 3.94 | 9.56 | 6.50 | n/m | ||||||
| Shares, m | — | — | — | — | 5 | 5 | 5 | 36 | 49 | 68 | 76 | +71.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (2) | (15) | (29) | (81) | (166) | (142) | (139) | +125.1% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | (84.4%) | ||||||
| Free cash flow | — | — | — | — | (2) | (15) | (29) | (81) | (166) | (142) | (139) | +125.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (4) | 6 | 105 | 239 | 191 | 646 | 646 | n/m | |||||
| Net debt | — | — | — | — | (1) | (11) | (110) | (237) | (198) | (657) | (564) | +241.7% | ||||||
| Shareholders’ equity | — | — | — | — | (4) | (23) | (52) | 241 | 191 | 647 | 551 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (307.79) | (47.46) | (39.28) | (77.72) | (35.65) | (69.67) | (35.6) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (1,153.49) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | 146.35 | 79.26 | (76.13) | (82.24) | (36.91) | (80.88) | (36.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 12 | 12 | 28 | 51 | 76 | — | +58.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Mineralys Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OCUL Ocular Therapeutix, Inc. | $1.4B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| KRSA Korsana Biosciences, Inc. | $1.4B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANAB AnaptysBio, Inc. | $1.4B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.4B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLYS Mineralys Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −7.91% (below 0%: shrinking) | — | 0.00% | |
| DMRA Galecto, Inc. | $1.4B | 24.7× | — | — | n/m | −877.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KARD KARDIGAN INC | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $1.4B | — | — | −3.93% | — | −119.15% | 92.54% | 0.00% |
Pay and ownership Proxy statement filed 8 April 2026
Ownership
Directors and executive officers, together
18.94%
Catalys Pacific Fund, LP
9.70%
Brian Taylor Slingsby, M.D., Ph.D., M.P.H.
9.70%
Entities affiliated with RA Capital Management, L.P.
9.60%
Srinivas Akkaraju, M.D., Ph.D.
7.23%
Samsara BioCapital, L.P.
7.12%
FMR LLC
6.09%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement